Helix OpCo, LLC

Based in the US, Helix OpCo, LLC operates as a provider of integrated genomics solutions, focusing on transforming healthcare through comprehensive genetic testing and actionable genomic insights. Helix OpCo, LLC, founded in 2015, is headquartered in San Mateo, US. The company specializes in genomics solutions and has conducted a total of 6 deals since its inception. In June 2021, Helix raised USD 50 mn in a Series C funding round, co-led by DFJ Growth, Kleiner Perkins, Mayo Clinic, Temasek Holdings, and Warburg Pincus.

The leadership team includes CEO Fábio Cabrini and James Lu, among others, who have a history in various innovative ventures in the life sciences sector. Helix offers integrated genomics solutions designed to transform healthcare and enhance medical research, diagnosis, treatment, and prevention. Their core product, Exome+, provides comprehensive genetic testing that empowers health systems, public health entities, and life sciences companies to leverage genomics effectively. By making genomics accessible and actionable, Helix enables its clients to deliver personalized healthcare solutions, thereby improving patient outcomes while reducing costs.

The company primarily serves health organizations in the United States, collaborating with hospitals, research institutions, and health systems to implement genomic insights into clinical practices, focusing on personalized medicine strategies. Helix generates revenue through partnerships and subscriptions with healthcare providers, research institutions, and life sciences companies. Their transactional structure involves providing genomic testing services and clinical insights that assist health systems in personalized medicine strategies. The flagship product, Exome+, is a key revenue driver, with pricing models varying based on specific tests and services.

Clients engage with Helix through direct-to-consumer offerings and B2B collaborations, enhancing clinical capabilities with the demand for genomic data and insights. In June 2021, following the completion of a USD 50 mn Series C funding round, Helix OpCo, LLC plans to accelerate its population genomics platform across health systems and life sciences companies. The funding will also support ongoing efforts in COVID-19 testing and viral surveillance. The company aims to expand its product offerings and reach new markets, enhancing its genomic solutions to improve healthcare delivery.